glp 1 euglycemic dka risk with SGLT2 inhibitors in diabetes patients It's important to study the

The SURMOUNT-1 trial showed that tirzepatide produced even greater weight loss in many patients

Indeed, at their peak in 2024, nearly 1 in 3 Americans taking a GLP-1 drug said they were getting it from a compounding pharmacy

Among natural options, berberine is most often compared to GLP-1 drugs because of its effects on blood sugar, insulin sensitivity, and appetite, though the mechanisms and strength of effect differ significantly

M., Wootten, D., Sexton, P

Novo Nordisk has sued Eli Lilly in New Jersey federal court, alleging that national ads for Zepbound and Mounjaro rely on outdated clinical trial comparisons that omit the highest available doses of Wegovy and Ozempicnewer options that Novo says materially undermine Lillys claims of broad superiority